The complexities of drug pricing come from pharmacy benefit managers and payers trying to maximize their margins, often using manufacturers as a pawn in their game. These middlemen own pharmacy benefit managers and retail pharmacies, and justify their bigger margins by the need to reinvest in R&D to develop life-saving drugs, like the COVID-19 vaccines.